Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Evotec Launches Innovation Centre for Fragment-Based Drug Discovery

  • Evotec launched the Innovation Centre for Fragment Based Drug Discovery (FBDD) that will offer an alternative approach for identifying novel, small molecule hits for a number of biological targets.

    The company has established a scientific board for this Innovation Centre to advise on the selection of high-quality biological targets for Evotec's pipeline of projects for partnering. The board will also advise on the development of these programs and identify areas to further enhance the technology base.

    Fragments are difficult to detect due to their weak interactions with protein target, Evotec explains. The company thus implemented a unique fragment screening platform, EVOlution, capable of identifying low molecular weight fragments in a biologically relevant environment.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »